Journal of Current Glaucoma Practice

Register      Login

VOLUME 11 , ISSUE 3 ( September-December, 2017 ) > List of Articles

ORIGINAL ARTICLE

Glaucoma Medication Preferences among Glaucoma Specialists in Mexico

Rafael Castaneda-Diez, Gabriel Lazcano-Gómez, Roberto Gonzalez-Salinas, Jesus Jimenez-Roman, Daniela Alvarez-Ascencio, Cindy Haro-Zuno, Mauricio Turati-Acosta, Magdalena Garcia-Huerta, Jesus Jimenez-Arroyo, Armando Castillejos-Chevez, Francisca Dominguez-Dueñas

Citation Information : Castaneda-Diez R, Lazcano-Gómez G, Gonzalez-Salinas R, Jimenez-Roman J, Alvarez-Ascencio D, Haro-Zuno C, Turati-Acosta M, Garcia-Huerta M, Jimenez-Arroyo J, Castillejos-Chevez A, Dominguez-Dueñas F. Glaucoma Medication Preferences among Glaucoma Specialists in Mexico. J Curr Glaucoma Pract 2017; 11 (3):97-100.

DOI: 10.5005/jp-journals-10028-1232

License: CC BY 3.0

Published Online: 01-12-2017

Copyright Statement:  Copyright © 2017; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Aim

To determine the glaucoma specialists' preferences for the different brands of topical glaucoma medications available in Mexico.

Materials and methods

A web-based survey was sent to 150 board-certified glaucoma specialists in Mexico, with 14 questions related to brand preferences for all glaucoma medications available in Mexico. Participants were asked to select each glaucoma medication class by brand and to state the factors leading to their choice.

Results

Data from 111 (74%) glaucoma specialists were collected. Imot (timolol 0.5%; Sophia, Mexico) was the preferred brand for the beta-blockers (BB) class by 71% (n = 79) of the participants. Azopt (brinzolamide 1%; Alcon Lab, US) was the preferred carbonic anhydrase inhibitor (CAI) by 54% (n = 60) of the glaucoma specialists. Lumigan (bimatoprost 0.01% and 0.03%; Allergan Inc., U.S.) was the first choice for the prostaglandin analogues (PGAs) in 62% (n = 70) of the answers. The most frequently prescribed alpha-agonist (AA) was Agglad (brimonidine 0.2%; Sophia Lab, Mexico) in 44% (n = 49) of the answers. Medication accessibility (31%), cost (29%), and recommended dose (23%) were the three main factors influencing the glaucoma specialists' preferences.

Conclusion

Medication cost and accessibility, as well as posology, remain the main factors influencing brand preferences among glaucoma doctors. In our professional opinion, the therapeutic effect must be the leading factor when prescribing topical medications in the daily practice, so that patients receive the best treatment option.

Clinical significance

This survey provides an understanding of the decision-making process when prescribing glaucoma medications by glaucoma specialists in a Latin American developing country. Ideally, patient treatment should be individualized and aimed to achieve the best results possible for their specific condition.

How to cite this article

Lazcano-Gomez G, Alvarez-Ascencio D, Haro-Zuno C, Turati-Acosta M, Garcia-Huerta M, Jimenez-Arroyo J, Castañeda-Diez R, Castillejos-Chevez A, Gonzalez-Salinas R, Dominguez-Dueñas F, Jimenez-Roman J. Glaucoma Medication Preferences among Glaucoma Specialists in Mexico. J Curr Glaucoma Pract 2017;11(3):97-100.


  1. Glaucoma: Elsevier Health Sciences; 2009. 1348p.
  2. Epidemiology of glaucoma: what's new? Can J Ophthalmol 2012 Jun;47(3):223-226.
  3. Management of glaucoma: focus on pharmacological therapy. Drugs Aging 2005;22(1):1-21.
  4. Selective laser trabeculoplasty (SLT) vs other treatment modalities for glaucoma: systematic review. Eye (Lond) 2014 Mar;28(3):249-258.
  5. Topical glaucoma therapy cost in Mexico. Int Ophthalmol 2014 Apr;34(2):241-249.
  6. Comparison of United States and Canadian glaucoma medication costs and price change from 2006 to 2013. J Ophthalmol 2015;2015:547960.
  7. Price, familiarity, and availability determine the choice of drug — a population-based survey five years after generic substitution was introduced in Finland. BMC Clin Pharmacol 2011 Dec 15;11:20.
  8. OIG Compliance Program Guidance for Pharmaceutical Manufacturers. Federal Register 2003 May 5;68(86). Available from: http://oig.hhs.gov/authorities/docs/03/050503FRCPGPharmac.pdf.
  9. Four-year incidence of open-angle glaucoma and ocular hypertension: the Los Angeles Latino Eye Study. Am J Ophthalmol 2012 Aug;154(2):315-325.
  10. Access to medicines by ambulatory health service users in Mexico: an analysis of the national health surveys 1994 to 2006. Salud Publica Mex 2010 Jan-Feb;52(1):30-38.
  11. Estimación de la población con seguro de salud en México mediante una encuesta nacional. Salud Publica Mex 2005;47 (Suppl 1):S22-S26.
  12. Essential medicines in the United States — why access is diminishing. N Engl J Med 2016 May 19;374(20):1904-1907.
  13. Influence of pharmaceutical marketing on prescription practices of physicians. J Indian Med Assoc 2013 Jan;111(1):47-50.
  14. A survey of German physicians in private practice about contacts with pharmaceutical sales representatives. Dtsch Arztebl Int 2010 Jun;107(22):392-398.
  15. What do Libyan doctors perceive as the benefits, ethical issues and influences of their interactions with pharmaceutical company representatives? Pan Afr Med J 2013 Apr 6;14:132.
  16. Attitudes and behaviors of psychiatry residents toward pharmaceutical representatives before and after an educational intervention. Acad Psychiatry 2005;29(1):33-39.
  17. Prescription trends-brand-name drugs vs generic. JAMA Intern Med 2016 Oct 1;176(10):1573-1574.
  18. Prevalence and predictors of generic drug skepticism among physicians: results of a national survey. JAMA Intern Med 2016 Jun 1;176(6):845-847.
  19. Pharmaceutical company influences on medication prescribing and their potential impact on quality use of medicines. J Clin Pharm Ther 2008 Oct;33(5):553-559.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.